nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—Hypoaesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.118	0.16	CcSEcCtD
Plerixafor—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.0518	0.0704	CcSEcCtD
Plerixafor—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.0471	0.0639	CcSEcCtD
Plerixafor—CXCR4—embryo—amyotrophic lateral sclerosis	0.0368	0.252	CbGeAlD
Plerixafor—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.0306	0.0416	CcSEcCtD
Plerixafor—CXCR4—medulla oblongata—amyotrophic lateral sclerosis	0.0235	0.161	CbGeAlD
Plerixafor—CXCR4—spinal cord—amyotrophic lateral sclerosis	0.021	0.143	CbGeAlD
Plerixafor—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0204	0.0277	CcSEcCtD
Plerixafor—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0195	0.0264	CcSEcCtD
Plerixafor—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0185	0.0252	CcSEcCtD
Plerixafor—CXCR4—nervous system—amyotrophic lateral sclerosis	0.0177	0.121	CbGeAlD
Plerixafor—CXCR4—central nervous system—amyotrophic lateral sclerosis	0.017	0.116	CbGeAlD
Plerixafor—CXCR4—cerebellum—amyotrophic lateral sclerosis	0.0166	0.114	CbGeAlD
Plerixafor—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.0156	0.0211	CcSEcCtD
Plerixafor—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0155	0.021	CcSEcCtD
Plerixafor—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0152	0.0207	CcSEcCtD
Plerixafor—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.014	0.019	CcSEcCtD
Plerixafor—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.0136	0.0184	CcSEcCtD
Plerixafor—CXCR4—brain—amyotrophic lateral sclerosis	0.0135	0.0924	CbGeAlD
Plerixafor—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.0133	0.018	CcSEcCtD
Plerixafor—CXCR4—HIV Life Cycle—VTA1—amyotrophic lateral sclerosis	0.0127	0.109	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.0125	0.017	CcSEcCtD
Plerixafor—Malaise—Riluzole—amyotrophic lateral sclerosis	0.0122	0.0165	CcSEcCtD
Plerixafor—Syncope—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0164	CcSEcCtD
Plerixafor—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0118	0.0161	CcSEcCtD
Plerixafor—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0156	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0155	CcSEcCtD
Plerixafor—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0154	CcSEcCtD
Plerixafor—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0152	CcSEcCtD
Plerixafor—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.011	0.0149	CcSEcCtD
Plerixafor—Shock—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0147	CcSEcCtD
Plerixafor—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0146	CcSEcCtD
Plerixafor—CXCR4—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.0108	0.0917	CbGpPWpGaD
Plerixafor—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0145	CcSEcCtD
Plerixafor—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0144	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.01	0.0136	CcSEcCtD
Plerixafor—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00995	0.0135	CcSEcCtD
Plerixafor—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00988	0.0134	CcSEcCtD
Plerixafor—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00981	0.0133	CcSEcCtD
Plerixafor—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00968	0.0131	CcSEcCtD
Plerixafor—CXCR4—HIV Life Cycle—CHMP2B—amyotrophic lateral sclerosis	0.00964	0.0823	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0095	0.0129	CcSEcCtD
Plerixafor—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00948	0.0129	CcSEcCtD
Plerixafor—Pain—Riluzole—amyotrophic lateral sclerosis	0.00941	0.0128	CcSEcCtD
Plerixafor—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00941	0.0128	CcSEcCtD
Plerixafor—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00906	0.0123	CcSEcCtD
Plerixafor—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00899	0.0122	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—VTA1—amyotrophic lateral sclerosis	0.00879	0.075	CbGpPWpGaD
Plerixafor—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00874	0.0119	CcSEcCtD
Plerixafor—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0087	0.0118	CcSEcCtD
Plerixafor—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.0081	0.011	CcSEcCtD
Plerixafor—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00789	0.0107	CcSEcCtD
Plerixafor—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00778	0.0106	CcSEcCtD
Plerixafor—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00753	0.0102	CcSEcCtD
Plerixafor—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00727	0.00987	CcSEcCtD
Plerixafor—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00699	0.00949	CcSEcCtD
Plerixafor—Rash—Riluzole—amyotrophic lateral sclerosis	0.00694	0.00941	CcSEcCtD
Plerixafor—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00693	0.00941	CcSEcCtD
Plerixafor—Headache—Riluzole—amyotrophic lateral sclerosis	0.00689	0.00935	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—CHMP2B—amyotrophic lateral sclerosis	0.00666	0.0568	CbGpPWpGaD
Plerixafor—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00653	0.00887	CcSEcCtD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—amyotrophic lateral sclerosis	0.00562	0.0479	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—amyotrophic lateral sclerosis	0.00514	0.0438	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.00506	0.0431	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF1—amyotrophic lateral sclerosis	0.00472	0.0402	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.00427	0.0364	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00339	0.0289	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TPK1—amyotrophic lateral sclerosis	0.00269	0.023	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.00258	0.022	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00258	0.022	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—amyotrophic lateral sclerosis	0.00237	0.0202	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.00221	0.0188	CbGpPWpGaD
Plerixafor—CXCR4—Disease—VTA1—amyotrophic lateral sclerosis	0.00215	0.0184	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.00186	0.0159	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00163	0.0139	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.00148	0.0126	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PLB1—amyotrophic lateral sclerosis	0.00148	0.0126	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.00146	0.0125	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.00133	0.0113	CbGpPWpGaD
Plerixafor—CXCR4—Disease—VCP—amyotrophic lateral sclerosis	0.00132	0.0112	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.00113	0.00962	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00103	0.00882	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000972	0.00829	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CST3—amyotrophic lateral sclerosis	0.000944	0.00805	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000921	0.00786	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000892	0.00761	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000792	0.00676	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000783	0.00668	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CASP9—amyotrophic lateral sclerosis	0.000686	0.00586	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000655	0.00559	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000637	0.00544	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB4—amyotrophic lateral sclerosis	0.000587	0.00501	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000579	0.00494	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000538	0.00459	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000505	0.00431	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000481	0.0041	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOE—amyotrophic lateral sclerosis	0.000454	0.00388	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000411	0.00351	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000387	0.0033	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000342	0.00292	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000318	0.00271	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—amyotrophic lateral sclerosis	0.000311	0.00266	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000263	0.00224	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	0.000202	0.00173	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	0.000191	0.00163	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	0.000172	0.00147	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	0.00013	0.00111	CbGpPWpGaD
